- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Prime Careers Spotlight
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Publications
- Quarterly Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Cell & Gene Pipeline Outlook
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Employer Market Insight Reports
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- Weight management: A holistic journey
- Climate change: An imprint on health
- Virtual reality: An emerging paradigm in health care
- Research
- AMCP Nexus 2025 research posters
- AMCP Nexus 2024 Research Posters
- 2024 AMCP Annual Meeting Research Posters
- Media
- Compliance / Legal
READ: Update on Prime's NCPDP telecom/claims F6 project
As communicated on Aug. 6, 2025, Prime Therapeutics (Prime) has initiated an enterprise project to comply with requirements regarding National Council for Prescription Drug Programs (NCPDP) retail pharmacy standards and Medicaid pharmacy subrogation standards outlined in a Centers for Medicare & Medicaid Finale Rule (CMS-0056-F).
Provided is an update on the status of Prime’s NCPDP telecoms/claims F6 project and a timeline of key accomplishments.
Client action will be required to uplift your internal systems to accommodate the mandated updates to claim data and participate in joint testing as we enter the testing phase in Q4 2026.
Timeline
In 2025, Prime has worked diligently to evaluate the requirements and establish a plan to execute these changes. Prime is taking a proactive approach to ensure we meet CMS requirements well ahead of the compliance deadline, minimizing risk and supporting uninterrupted service for all stakeholders.
Key milestones
- Q1 2026: Completion of requirements for adjudication platforms
- Q2 2026: Program and project planning complete
- Q4 2026: Development complete for core and ancillary applications
- Q4 2026 – Q3 2027: Internal and joint testing completed
- Q3 2027: Transition activities begin
- April 14, 2028: Regulatory compliance achieved
How Prime will partner with our clients
Action will be needed from Prime and clients to comply with the requirements, and we are committed to being an active partner throughout. Prime will routinely engage our clients to support them through this transition by:
- Assessing current systems and processes: Prime will work with clients to review existing file formats, workflows and dependencies to identify areas impacted by the upcoming changes.
- Planning client testing: Prime will schedule time for collaborative testing phases with clients between October 2026 and August 2027 to validate compliance and ensure smooth integration.
Prime recommends that clients begin planning to ensure the necessary resources are available to support file changes, process updates and testing activities related to the transition.
For clients migrating to Judi, Prime is working to align NCPDP F6 compliance activity with the Judi migration schedule to reduce overlapping efforts and streamline resource management.
Next steps
Prime will continue to provide updates that include detailed information and revised timelines, enabling all parties to effectively allocate resources and prepare for testing and data exchanges. We will provide these updates on a quarterly basis, with supplemental communication as necessary.
Questions
Please reach out to your Prime account team representative.